Skip to main content

Table 5 Changes in secondary efficacy measures in the sitagliptin and voglibose group

From: Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial

Variable

Sitagliptin

Voglibose

Between-group difference

 

Mean ± SD

P value

Mean ± SD

P value

P value

Glucose

     

Baseline at 0W

145 ± 58

 

133 ± 42

 

0.304

At 24W

127 ± 26

 

133 ± 27

 

0.354

24W-0W

-23 ± 60

0.047

1 ± 43

0.916

0.083

HbA1c

     

Baseline at 0W

7.1 ± 0.7

 

6.9 ± 0.5

 

0.273

At 24W

6.4 ± 0.4

 

6.7 ± 0.5

 

0.026

24W-0W

-0.7 ± 0.6

<0.0001

-0.3 ± 0.4

0.0004

0.002

GIP

     

Baseline at 0W

191 ± 214

 

159 ± 211

 

0.517

At 24W

149 ± 161

 

162 ± 148

 

0.759

24W-0W

-21 ± 226

0.314

0.6 ± 1.6

0.041

0.749

CD34

     

Baseline at 0W

1.1 ± 0.7

 

0.9 ± 0.6

 

0.239

At 24W

1.1 ± 0.5

 

0.9 ± 0.7

 

0.160

24W-0W

0.1 ± 0.5

0.435

0.0 ± 0.5

0.772

0.430

Total cholesterol

     

Baseline at 0W

184 ± 27

 

185 ± 33

 

0.944

At 24W

178 ± 29

 

183 ± 37

 

0.522

24W-0W

-3 ± 30

0.603

0 ± 29

0.991

0.709

Triglyceride

     

Baseline at 0W

155 ± 107

 

141 ± 74

 

0.486

At 24W

132 ± 62

 

127 ± 72

 

0.803

24W-0W

-15 ± 94

0.391

-13 ± 52

0.190

0.905

HDL-C

     

Baseline at 0W

51 ± 12

 

56 ± 16

 

0.106

At 24W

52 ± 14

 

53 ± 15

 

0.930

24W-0W

0.8 ± 7.9

0.551

-3.6 ± 8.2

0.010

0.021

Adiponectin

     

Baseline at 0W

11.0 ± 8.3

 

13.3 ± 8.7

 

0.222

At 24W

11.7 ± 8.8

 

12.9 ± 7.3

 

0.528

24W-0W

0.5 ± 1.8

0.092

-0.3 ± 2.9

0.539

0.150

MDA-LDL

     

Baseline at 0W

106 ± 34

 

110 ± 37

 

0.658

At 24W

113 ± 34

 

109 ± 36

 

0.591

24W-0W

9 ± 32

0.118

1 ± 38

0.860

0.364

8-OHdG

     

Baseline at 0W

11.7 ± 7.9

 

13.5 ± 10.0

 

0.392

At 24W

11.4 ± 7.4

 

14.8 ± 14.6

 

0.221

24W-0W

-0.2 ± 10.0

0.903

1.5 ± 16.9

0.596

0.605

hs-CRP

     

Baseline at 0W

3869 ± 9072

 

1358 ± 2511

 

0.099

At 24W

1933 ± 5101

 

661 ± 691

 

0.147

24W-0W

-1929 ± 6798

0.098

-380 ± 1186

0.059

0.186

PTX-3

     

Baseline at 0W

1.8 ± 1.0

 

2.4 ± 2.7

 

0.206

At 24W

1.5 ± 0.8

 

1.6 ± 0.8

 

0.557

24W-0W

-0.3 ± 0.7

0.006

-0.3 ± 1.2

0.104

0.974

e-GFR

     

Baseline at 0W

75 ± 22

 

71 ± 15

 

0.304

At 24W

69 ± 19

 

72 ± 16

 

0.411

24W-0W

-5 ± 12

0.014

0 ± 9

0.903

0.036

BNP, pg/ml

     

Baseline at 0W

39 ± 48

 

34 ± 35

 

0.600

At 24W

40 ± 41

 

28 ± 24

 

0.160

24W-0W

1 ± 40

0.923

-5 ± 22

0.164

0.443

  1. GIP gastric inhibitory peptide, GLP-1 glucagon-like peptide-1, CD34 C-peptide, MDA-LDL malondialdehyde-modified low density lipoprotein, 8-OHdG 8-hydroxy-2′-deoxyguanosine, hs-CRP high-sensitive C-reactive protein, PTX-3pentraxin-3, eGFR estimated glomerular filtration rate, BNP B-type natriuretic peptide